COX-2 Script Spike Seen In Patients At Low Risk For NSAID Adverse Events
This article was originally published in The Tan Sheet
Executive Summary
Patients at low risk for gastrointestinal side effects from NSAIDs accounted for a more than 60% jump in COX-2 prescriptions since the introduction of the drug class five years ago, a study in the Jan. 24 Archives of Internal Medicine finds
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning